SYK vs BSX — Key Metrics

Metric SYK (STRYKER CORP) BSX (BOSTON SCIENTIFIC CORP)
Price318.1543.64
Market Cap121.12 Billion63.26 Billion
P/E (TTM)33.6318.34
P/B (Quarterly)4.7372.506
P/S (TTM)4.613.0
Net Profit Margin (TTM)13.816.6
Gross Margin (TTM)65.369.1
ROE (TTM)15.613.9
Revenue Growth YoY (TTM)n/an/a

Upfront Investment - S&P 500 Stock Comparison & AI Analysis

AI-powered analysis and comparison tools for S&P 500 stocks, helping investors make data-driven decisions with delayed market data and portfolio modeling.

STRYKER CORP
vs
 
BOSTON SCIENTIFIC CORP
 
STRYKER CORP
vs
 
BOSTON SCIENTIFIC CORP
Performance Comparison
AI Model Recommendation
SYK · STRYKER CORP

Greatly Underperform

-64
UnderperformOutperform
BSX · BOSTON SCIENTIFIC CORP

Greatly Outperform

84
UnderperformOutperform
Recommendation Summary

Stock SYK is projected to greatly underperform the market, stock BSX is projected to greatly outperform the market. Upfront Recommendation: BSX.

Financial Metrics
Prices delayed ~15 min
SYK Metrics BSX
$318.15 Price $43.64
— Market Capitalization —
33.63 Price to Earnings Ratio 18.34
4.61 Price to Sales 3.0
26.49 Price to FCF Ratio 18.99
7.05 Price to Gross Profit 4.34
72.05 Price to R&D 29.3
8.54 Price to Current Assets 7.75

SYK vs BSX at a glance

Stryker Corp (SYK) and Boston Scientific Corp (BSX) are both Medical Devices companies in the Healthcare sector. SYK is the larger, at $121.1 billion in market value against $63.3 billion for BSX, about 1.9 times the size.

On trailing-twelve-month figures, SYK trades at 33.6 times trailing earnings and BSX at 18.3; net profit margins are 13.8% and 16.6%.

The Upfront Investment model currently rates SYK Greatly Underperform and BSX Greatly Outperform as of November 18, 2026. The rating ranks the model's medium-term return forecast against the other stocks it scores; it is a statistical forecast, not investment advice.